Alert | 27.03.2020

Covid-19: regulatory steps taken by AIFA in relation to the pharmacological treatment of the desease


Marketing & Communication
marketing@lcalex.it

COVID-19 represents a new pathogenic element for the whole world. Consequently, to date, there are no specific therapies to cure or prevent it, as no medicine has been studied for the treatment of this specific Coronavirus.

AIFA (Italian Medicines Agency) therefore established a specific crisis unit and intervened by taking various initiatives to face the emergency.

The Life Science Team analyzed them in the new Alert.

Read it here!


Marketing & Communication
marketing@lcalex.it

Life Sciences

Also in the Life Sciences industry, our dedicated team combines cross-departmental skills and expertise to support a wider range of clients. We work with entrepreneurs, institutions, investors and domestic and international funds operating in the Life Science and Healthcare fields, providing full multi-disciplinary assistance, based on the experience and the real and in-depth knowledge of the specific issues of this industry.
LINK

You might also be interested in

07.05.2020
Import of facemasks, medical devices and ppe: administrative and criminal penalti ...

What are the main consequences – both administrative and criminal − in case of import and distribution of MD and PPE? Read more.

07.04.2020
HealthCare: news & business opportunities – Italy

Covid-19: find out in the document the news and opportunities in Italy for the HealthCare sectors: medical devices, pharma and more.

08.07.2019
Regulation (EU) 2017/745: new provisions for manufacturing and supply of medical d ...

An in-depth analysis of Regulation n.2017/745 recent provisions to which, starting from now, companies operating in the Medical Devices sec ...